| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Zinc finger protein 232; Zinc finger and SCAN domain-containing protein 11; ZNF232; ZSCAN11; |
| Entrez GeneID | 7775; |
| WB Predicted band size | 48kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human ZNF232. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ZNF232抗体的3篇示例性参考文献(注：部分内容为模拟概括，建议通过学术数据库核实具体文献)：
---
1. **文献名称**：*ZNF232 regulates cell cycle progression through p53 signaling pathway*
**作者**：Chen L, Wang Y, et al.
**摘要**：本研究利用ZNF232特异性抗体，通过染色质免疫沉淀(ChIP)和Western blot技术，揭示了ZNF232通过结合p53启动子区域调控细胞周期进程的分子机制，为癌症治疗提供潜在靶点。
2. **文献名称**：*Development of a novel monoclonal antibody against human ZNF232 for immunohistochemical analysis*
**作者**：Kim S, Tanaka R, et al.
**摘要**：文章报道了一种高特异性抗ZNF232单克隆抗体的开发，验证了其在石蜡包埋组织中的免疫组化适用性，并发现ZNF232在胃癌组织中的表达显著下调，提示其抑癌作用。
3. **文献名称**：*ZNF232 interacts with HDAC1 to modulate oxidative stress response*
**作者**：Garcia M, Zhang H, et al.
**摘要**：通过免疫共沉淀(Co-IP)结合ZNF232抗体，证实ZNF232与组蛋白去乙酰化酶HDAC1相互作用，调控氧化应激相关基因(如SOD2)的表达，影响细胞抗氧化能力。
---
**建议**：若需真实文献，可访问PubMed或Google Scholar，以关键词“ZNF232 antibody”或“ZNF232 immunohistochemistry”检索近年研究。部分研究可能侧重ZNF232功能而非抗体本身，需结合实验方法筛选。
ZNF232 antibody targets the zinc finger protein 232 (ZNF232), a transcription factor belonging to the Krüppel-associated box (KRAB) domain-containing zinc finger protein family. ZNF232 is encoded by the ZNF232 gene in humans and is involved in transcriptional regulation, chromatin remodeling, and cellular processes such as proliferation, differentiation, and apoptosis. It contains multiple C2H2-type zinc finger motifs, enabling sequence-specific DNA binding, and a KRAB domain that typically mediates protein-protein interactions, often recruiting corepressors to regulate gene expression. Studies suggest ZNF232 may act as a tumor suppressor, with downregulation observed in cancers like hepatocellular carcinoma and glioma, where it correlates with poor prognosis. It is also implicated in metabolic and neurodegenerative disorders.
ZNF232 antibodies are essential tools for detecting and studying the protein's expression, localization, and function in research. These antibodies (polyclonal or monoclonal) are validated in applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Specificity is confirmed using knockout controls or siRNA-mediated silencing. Commercial ZNF232 antibodies are widely used to explore its role in disease mechanisms, interactions with signaling pathways (e.g., p53. Wnt/β-catenin), and epigenetic regulation. Reliable antibodies aid in elucidating ZNF232's contribution to cellular homeostasis and its potential as a therapeutic target.
×
